Synta Announces Presentations at the 2015 ASCO Annual Meeting
Feasibility of Ganetespib Combination Therapy Demonstrated in Three Investigator-Sponsored Trials
STA-12-8666 Results in Pediatric Sarcoma Models Highlighted in Poster Discussion Session
The Company also announced that preclinical results for its lead HDC candidate, STA-12-8666, in pediatric sarcoma will be presented at the ASCO Annual Meeting. STA-12-8666 is a conjugate of an Hsp90 inhibitor and SN-38, the active metabolite of the widely used drug irinotecan.
Details of the poster presentations are provided below:
Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib combined with weekly paclitaxel in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
Abstract #: 5578
Date and Time:
Location:
S Hall A2
Presenter: Isabelle Ray-Coquard, M.D., Centre Léon
Bérard,
Activity of Hsp90 inhibitor drug conjugate (HDC) STA-12-8666 in preclinical models of pediatric sarcoma.
Abstract #: 10025
Date and Time:
Location: S Hall A2
(Poster); S504 (Discussion)
Presenter:
Phase I study of ganetespib, capecitabine, and radiation in rectal cancer.
Abstract #: 3596
Date and Time:
Location:
S Hall A2
Presenter: Bassel F. El-Rayes, M.D.,
A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers.
Abstract #: 8064
Date and Time:
Location:
S Hall A2
Presenter: Gregory J. Riely, M.D.,
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. Synta’s lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in several clinical trials including the pivotal GALAXY-2 Phase 3 trial in non-small cell lung cancer. Building on its extensive expertise in the science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor Drug Conjugate (HDC) small molecule drug development program. IND enabling studies have commenced for the first clinical candidate from the HDC program, STA-12-8666, and preclinical evaluation of additional HDC candidates is ongoing. For more information, please visit www.syntapharma.com.
Safe Harbor Statement
This media release may contain forward-looking statements about
View source version on businesswire.com: http://www.businesswire.com/news/home/20150528006617/en/
Source:
Investors:
Synta Pharmaceuticals Corp.
Daniel Cole,
781-541-7250
[email protected]
or
Argot
Partners
Andrea Rabney, 212-600-1494
[email protected]
or
Media:
Argot
Partners
Eliza Schleifstein, 917-763-8106
[email protected]